1. Double-Dose, New-Generation Proton Pump Inhibitors Do Not Improve Helicobacter pylori Eradication Rate
- Author
-
Dong Il Park, Jung Sik Park, Sang Jun Hwang, Hong Joo Kim, Hyo Sun Choi, Byung Ik Kim, Yong Kyun Cho, Woo Kyu Jeon, and Chong Il Sohn
- Subjects
medicine.medical_specialty ,biology ,business.industry ,medicine.drug_class ,Gastroenterology ,Rabeprazole ,Proton-pump inhibitor ,General Medicine ,Helicobacter pylori ,biology.organism_classification ,Esomeprazole ,Infectious Diseases ,Tolerability ,Clarithromycin ,Internal medicine ,medicine ,business ,Omeprazole ,medicine.drug ,Pantoprazole - Abstract
Background: Up to present, omeprazole plus two antibiotics are used for Helicobacter pylori eradication therapy . Few studies have compared double-dose new-generation, proton pump inhibitors (PPI) with omeprazole. Therefore, we conducted a randomized, prospective study to evaluate differences in H. pylori eradication rates by PPI type. Material and Methods: Between January 2006 and December 2006, 576 consecutive patients with proven H. pylori infection were enrolled prospectively. Four different PPIs [omeprazole 20 mg b.i.d. (old generation), or pantoprazole 40 mg b.i.d., rabeprazole 20 mg b.i.d., or esomeprazole 40 mg b.i.d. (new generation)] were added to clarithromycin (500 mg b.i.d.) and amoxicillin (1 g b.i.d.) for 1 week. Results: By intention-to-treat analysis, no difference was found between the eradication rates of these four PPIs: 64.9% (omeprazole, n = 148), 69.3% (pantoprazole, n = 140), 69.3% (rabeprazole, n = 140), and 72.9% (esomoprazole, n = 148). When eradication rates were analyzed according to whether patients had an ulcer or not on a per-protocol basis, no difference was found between the eradication rates of the four PPIs. However, side-effects were more common in the esomeprazole-based triple therapy group than in the other groups (p
- Published
- 2007